Thanks for posting ! I see in the analysis that the NPV of $2.3 billion / $23/ADR is a "risk-adjusted" valuation based on 85% probability of success of the Remestemcel-L product and a 40% probability of success on the Advanced Heart Failure Revascor product. If both of these hit we're looking at a much higher valuation. And none of the indicated valuation estimate includes any of the other pipeline in development. Will be nice to see how this rolls over next year or so.
$MESO Mesoblast Ltd Receives a Buy from Cantor Fitzgerald with a $23 price target., page-34
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |